AMAG Pharmaceuticals (AMAG) Given Coverage Optimism Score of 0.29

Media headlines about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.29 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.414248399331 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

• AMAG Pharmaceuticals : Community Salem resident named to board of March of Dimes (4-traders.com)
• Kornitzer Capital Management Inc. KS Increases Stake in Pfizer, Inc. (NYSE:PFE) (expressnewsline.com)
• Trading Monitor: Focusing on Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Sparta Review (spartareview.com)
• AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Given Hold Rating at Cantor Fitzgerald (bulhufas.com)
• AMAG Pharmaceuticals, Inc. (AMAG) vs. Quidel Corporation (QDEL): Comparing the Diagnostic Substances Industry’s … – StockNewsGazette (stocknewsgazette.com)

Several equities analysts have weighed in on the company. BidaskClub cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen and Company reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Barclays PLC reaffirmed a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a report on Monday, May 15th. Deutsche Bank AG set a $24.00 price objective on AMAG Pharmaceuticals and gave the company a “hold” rating in a report on Friday, July 7th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, July 24th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.09.

AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 17.15 on Friday. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83. The company’s market cap is $605.19 million. The stock has a 50 day moving average price of $18.88 and a 200 day moving average price of $20.58.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The business had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. During the same quarter last year, the business posted $1.45 earnings per share. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. On average, equities analysts forecast that AMAG Pharmaceuticals will post ($1.37) earnings per share for the current year.

In other news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by [[site]] and is the property of of [[site]]. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at [[permalink]].

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.